RecruitingPhase 1NCT06578676
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
A Clinical Study to Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Sponsor
Hyundai Pharm
Enrollment
56 participants
Start Date
Jun 20, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
Eligibility
Min Age: 19 Years
Inclusion Criteria3
- Signed informed consent
- Age: 19 and over , healthy volunteer
- Body mass index (BMI): 18.5≤BMI≤29.9 kg/m²
Exclusion Criteria2
- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal
- Clinically relevant findings(e.g. blood pressure, electrocardiogram(ECG); physical and gynecological examination, laboratory examination)
Interventions
DRUGEmpagliflozin 25 MG
PO, QD
DRUGEzetimibe/Rosuvastatin 10/10mg
PO, QD
DRUGEmpagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
PO, QD
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06578676
Related Trials
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT0729648446 locations
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
NCT071694221 location
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
NCT068364791 location
High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes
NCT066884611 location
Exercise and Protein Efficiency in T2D
NCT074770671 location